<DOC>
	<DOC>NCT00141791</DOC>
	<brief_summary>The primary objective of the study is to assess the efficacy and safety of etanercept 25 mg given twice weekly in subjects with moderate to severe persistent asthma.</brief_summary>
	<brief_title>Study Evaluating Etanercept in Moderate to Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Moderate to severe persistent asthma for at least 1 year Demonstrated reversibility of at least 9% and (FEV1) 50% to 80% predicted Subjects must be on a highdose inhaled corticosteroid (ICS) Previous treatment with etanercept Current use of cigarettes Significant concurrent medical conditions at the time of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Anti-Asthmatic Agents</keyword>
	<keyword>Receptors</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
</DOC>